The Amgen-Horizon Therapeutics merger isn’t quite over the finish line, because — in accordance with consumer protection and anti-competition laws — the FTC is seeking public comment on the consent order it recently issued allowing Amgen’s proposed $27.8 billion buyout of the Irish pharmaceutical company to proceed.